KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) Operating Income: 2020-2025

Historic Operating Income for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Sep 2025 value amounting to -$172.2 million.

  • Recursion Pharmaceuticals' Operating Income fell 75.08% to -$172.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$723.6 million, marking a year-over-year decrease of 83.57%. This contributed to the annual value of -$479.0 million for FY2024, which is 36.83% down from last year.
  • Latest data reveals that Recursion Pharmaceuticals reported Operating Income of -$172.2 million as of Q3 2025, which was up 2.28% from -$176.2 million recorded in Q2 2025.
  • In the past 5 years, Recursion Pharmaceuticals' Operating Income registered a high of -$30.5 million during Q1 2021, and its lowest value of -$191.4 million during Q1 2025.
  • Over the past 3 years, Recursion Pharmaceuticals' median Operating Income value was -$99.5 million (recorded in 2023), while the average stood at -$124.4 million.
  • Its Operating Income has fluctuated over the past 5 years, first tumbled by 153.94% in 2021, then grew by 6.12% in 2022.
  • Over the past 5 years, Recursion Pharmaceuticals' Operating Income (Quarterly) stood at -$65.0 million in 2021, then rose by 6.12% to -$61.0 million in 2022, then plummeted by 62.23% to -$98.9 million in 2023, then tumbled by 85.76% to -$183.8 million in 2024, then slumped by 75.08% to -$172.2 million in 2025.
  • Its Operating Income was -$172.2 million in Q3 2025, compared to -$176.2 million in Q2 2025 and -$191.4 million in Q1 2025.